<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422055</url>
  </required_header>
  <id_info>
    <org_study_id>P130201J</org_study_id>
    <nct_id>NCT03422055</nct_id>
  </id_info>
  <brief_title>Study of Tolerance, Biodistribution and Dosimetry of Fucoidan Radiolabeled by Technetium-99m</brief_title>
  <acronym>NANO-ATHERO</acronym>
  <official_title>Study of Tolerance, Biodistribution and Dosimetry of Fucoidan Radiolabeled by Technetium-99m</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The development of an innovative imaging agent capable of non-invasively detecting vulnerable&#xD;
      plaques is a major objective of research in cardiovascular pathology. Such a tool would allow&#xD;
      for better identification of patients at risk of acute events. We showed that 99mTechnetium&#xD;
      (99mTc)-labeled fucoidan was able to target P-selectine expressed by activated platelets in&#xD;
      vitro in humans and in vivo in a model of abdominal aortic aorta thrombus and endocarditic&#xD;
      vegetations in rats.&#xD;
&#xD;
      One of the objectives of the Nanoathero program is the clinical translation of the&#xD;
      99mTc-fucoidan. As a first step, we will assess the safety, biodistribution and dosimetry of&#xD;
      this new radiopharmaceutical in humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The development of an innovative imaging agent capable of non-invasively detecting vulnerable&#xD;
      plaques is a major objective of research in cardiovascular pathology. Such a tool would allow&#xD;
      for better identification of patients at risk of acute events. We showed that&#xD;
      99mTechnetium-labelled fucoidan was able to target P-selectin expressed by activated&#xD;
      platelets in vitro in humans and in vivo in a model of abdominal aortic aorta thrombus and&#xD;
      endocarditic vegetations in rats.&#xD;
&#xD;
      NanoAthero is a monocenter, interventional, open-labeled, first-in-man study to evaluate&#xD;
      tolerance of 99mTc-Fucoïdane in healthy volunteers.&#xD;
&#xD;
      Healthy volunteers registered in the Bichat Centre for Clinical Investigations (CCI) will be&#xD;
      contacted by email to participate in the study. The selection visit will be organized by the&#xD;
      CCI according to the availability of the healthy volunteer.&#xD;
&#xD;
      V0: selection/inclusion visit: pre-audit of eligibility criteria, demographic data, medical&#xD;
      examination, clinical examination and measurement of vital signs, urinary pregnancy test for&#xD;
      women of childbearing potential, blood samples (hematology and biochemistry analyses) and&#xD;
      12-lead ECG.&#xD;
&#xD;
      V1: 99mTc-Fucoidan scintigraphy. The delay between the inclusion visit and the completion of&#xD;
      the scan is 30 ± 7 days. The visit will include verification and confirmation of the consent&#xD;
      of the healthy volunteer, clinical examination and measurement of vital signs, urinary&#xD;
      pregnancy test for women of childbearing age, blood samples (hematology and biochemistry&#xD;
      analyses) and 12-lead ECG.&#xD;
&#xD;
      Whole-body scintigraphic acquisitions will be performed 30 min, 90 min, 3 hours, 6 hours and&#xD;
      24 hours after intravenous administration of 99mTc-Fucoidan for the evaluation of&#xD;
      biodistribution and dosimetry. Vital signs will be monitored 5 min, 15 min, 30 min, 60 min,&#xD;
      90 min, 3 hours, 6 hours and 24 hours after intravenous administration of 99mTc-Fucoidan.&#xD;
      24-hour urine collection will be performed for dosimetry assessment.&#xD;
&#xD;
      V2: End of research visit will be carried out 7 ± 3 days after administration of&#xD;
      99mTc-Fucoidan, and will include medical interview, clinical examination, measurement of&#xD;
      vital signs, blood samples (hematology and biochemistry analyses) and 12-lead ECG.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">February 2018</start_date>
  <completion_date type="Anticipated">July 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and serious adverse events after 99m Tc-Fucoidan IV administration</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Number and percentage of subjects with adverse events and serious adverse events based on clinical, ECG and biological monitoring until 7 days after 99mTc-Fucoidan intravenous administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biodistribution of 99mTc-Fucoidan after intravenous administration</measure>
    <time_frame>during 24h after injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dosimetry of 99mTc-Fucoidan after intravenous administration</measure>
    <time_frame>during 24h after injection</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>99mTc-Fucoidan SPECT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>99mTc-Fucoidan SPECT</intervention_name>
    <description>Intravenous administration of 99mTc-Fucoidan on healthy volunteers.</description>
    <arm_group_label>99mTc-Fucoidan SPECT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Adult volunteer&#xD;
&#xD;
          -  No chronic progressive disease&#xD;
&#xD;
          -  Absence of long term medication&#xD;
&#xD;
          -  BMI between 18 and 35&#xD;
&#xD;
          -  Absence of chronic infection by HIV, HVB, HCV&#xD;
&#xD;
          -  Absence of significant biological abnormality in the screening report&#xD;
&#xD;
          -  Affiliation to a social security system or CMU&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Females with childbearing potential as well as males should use effective&#xD;
             contraceptive methods&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Pregnant or nursing woman&#xD;
&#xD;
          -  Person of exclusion period of research protocol&#xD;
&#xD;
          -  Person in detention by judicial or administrative decision&#xD;
&#xD;
          -  Protected person (maintenance of justice, tutelage, legal guardianship)&#xD;
&#xD;
          -  Person unable to express consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Le Guludec, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique Le Guludec, MD, PhD</last_name>
    <phone>01.40.25.84.13</phone>
    <phone_ext>+33</phone_ext>
    <email>dominique.leguludec@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>François Rouzet, MD, PhD</last_name>
    <phone>01.40.25.64.11</phone>
    <phone_ext>+33</phone_ext>
    <email>francois.rouzet@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Groupe Hospitalier Bichat - Claude Bernard</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>February 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>February 2, 2018</last_update_submitted>
  <last_update_submitted_qc>February 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety 99mTc-Fucoïdane scintigraphy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fucoidan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

